-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Epithelial ovarian cancer (EOC) is the deadliest gynecological cancer with a 5-year survival rate of only 47 %
.
The average lifetime risk of EOC in women is 1.
47
Salpingo-oophorectomy (RRSO) is the most effective preventive method, reducing the risk of EOC by up to 96%
.
To optimize risk reduction, guidelines recommend that carriers of pathogenic variants in BRCA1 and BRCA2 receive RRSO at ages 35-40 and 40-45 years, respectively
Salpingo-oophorectomy (RRSO) is the most effective preventive method, reducing the risk of EOC by up to 96%
However, although the risk of ovarian cancer was significantly reduced after RRSO, the risk of developing peritoneal cancer (PC) remained
.
The etiology of peritoneal cancer has not been fully elucidated, but it may be related to serous tubal intraepithelial carcinoma (STIC)
To assess the risk of peritoneal cancer in women with and without serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy
We searched EMBASE, MEDLINE and Cochrane databases for studies published before September 2020 in women receiving RRSO who carry a BRA1/2 pathogenic variant
.
The primary outcome measures were the hazard ratio of developing peritoneal cancer in BRCA1/2 pathogenic variant carriers with and without STIC at the time of RRSO, and the risk of peritoneal cancer at 5 and 10 years after surgery
The primary outcome measures were the hazard ratio of developing peritoneal cancer in BRCA1/2 pathogenic variant carriers with and without STIC at the time of RRSO, and the risk of peritoneal cancer at 5 and 10 years after surgery
Cumulative risk of peritoneal cancer in patients with and without STIC
Cumulative risk of peritoneal cancer in patients with and without STICWe screened 17 eligible studies covering a total of 3121 women, 115 of whom had serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy
.
During follow-up, the ratio of the risk of developing PC in patients with STIC to the risk of developing PC in individuals without STIC was estimated to be 33.
3121 115 The ratio of the risk of developingPC in patients with STIC to the risk of developing PC in individuals without STIC was estimated to be 33.
Predicted risk of peritoneal cancer in individuals with and without STIC
Predicted risk of peritoneal cancer in individuals with and without STICIn conclusion, carriers of a BRCA1/2 pathogenic variant with serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy have an increased risk of subsequent peritoneal carcinoma over time
BRCA1/2 pathogenic variant carriers with serous tubal intraepithelial carcinoma at the time of salpingo-oophorectomy and subsequently have an increased risk of developing peritoneal carcinoma over time having serous tubal at the time of salpingo-oophorectomy Carriers of a BRCA1/2 pathogenic variant in intraepithelial carcinoma have an increased risk of subsequent peritoneal carcinoma over time
Original source:
Original source:Miranda P.
leave a message here
